ESR1 and breast carcinoma: We initially screened drug combinations using the three ERα + breast cancer cell lines, MCF7 (tamoxifen-sensitive), MCF7-V (a more tamoxifen-tolerant variant of MCF7) [17, 84], and MCF7/LCC2 (tamoxifen-resistant) [85].